Rachel M. Koldej is a Hematologist-Oncologist based in Melbourne, VIC, Australia. She looks after people with conditions that affect the blood, bone marrow, and lymph system. It can be a lot to take in at first, so her approach is steady and practical. Over time, many patients find it easier to talk through worries, test results, and what treatment might mean for day-to-day life.
Rachel works with adults who need help with blood cancers and related problems. This can include different types of lymphoma and leukemia, plus conditions like multiple myeloma and myelodysplastic syndrome. She also sees people with ongoing issues such as anaemia, low platelets (thrombocytopenia), and aplastic anaemia. In some cases, blood and immune complications like sepsis also come up, especially when someone is dealing with treatment or a weakened immune system.
Her work can involve complex care paths. Bone marrow transplant is one part of the picture for some patients, and she supports people through what comes before and after transplant. She also helps manage graft versus host disease (GvHD) when it happens. At times, treatment plans may include managing symptoms and keeping blood counts stable, alongside cancer care.
Many of the cancers Rachel treats are slow-growing, but not all of them are. Some patients may have follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukaemia (CLL), or other related diagnoses. Others may be facing quicker changes, such as acute myeloid leukaemia (AML). She focuses on making sure people understand the next steps, what to watch for, and why a particular option is chosen.
Rachel’s clinical training sits in haematology and oncology, which means she’s used to working with blood counts, scans, and marrow tests, and coordinating care when more than one specialist is involved. In a busy setting, this kind of continuity matters. At the same time, she keeps things human. When treatment affects energy levels, work, and family routines, that’s part of the conversation, not just the medical paperwork.
Research and newer treatment approaches also matter in this field, and Rachel stays up to date with what’s changing in cancer care. Clinical trials can be relevant for some people, but the right fit depends on the individual case and timing.
